Centella Asiatica Exosome Serum Shows Pore, Elasticity, and Hydration Gains in 28-Day Trial
Centella asiatica has been a fixture of K-beauty formulations for years, valued primarily for its calming, anti-inflammatory properties. But since 2025, the research focus has shifted to a more precise application of the plant’s biology: extracellular vesicles (EVs), nanoscale particles released by plant cells that carry concentrated bioactive cargo.
What Extracellular Vesicles Are
Extracellular vesicles are membrane-bound particles, 30 to 200 nanometers in diameter, that cells use to transmit biological signals. Plant-derived EVs carry a concentrated payload of growth factors, proteins, lipids, and small molecules from the source plant. In theory, they offer more targeted cellular-level delivery than conventional plant extracts.
For Centella asiatica, the primary active compounds, asiaticoside and madecassoside, are already known to stimulate collagen synthesis through the TGF-beta pathway and suppress the NF-kB inflammatory cascade. CICA-derived EVs are being studied as a delivery mechanism that concentrates and enhances these actions.
The 28-Day Trial Results
A 2025 pilot study published in Cosmetics (MDPI) enrolled 20 healthy adults with a mean age of 36.5 years (4 male, 16 female). Participants applied a serum containing CICA leaf and callus extracellular vesicles twice daily for 28 days. Skin hydration, elasticity, melanin content, wrinkle depth, redness, and pore size were assessed at baseline and at days 7, 14, 21, and 28.
All assessed parameters showed statistically significant improvement in the treatment group (p<0.001). The placebo group showed no significant changes.
A separate 2025 clinical trial tested a CICA exosome ampoule (ExoGlow) in 20 participants with a mean age of 50.7 years over two weeks. Results showed a 17.9% reduction in mean pore area, 26.9% decrease in pore density, and 9.0% decrease in surface roughness.
From Soothing to Structural
The shift in how CICA is positioned matters. The conventional role has been calming reactive or post-procedure skin. The EV data is pointing toward something different: direct collagen synthesis stimulation, extracellular matrix remodeling, and structural repair rather than just inflammation suppression.
Pore size and skin elasticity improving simultaneously is clinically relevant because they share a common mechanism. Reduced collagen and elastin in the dermis causes the tissue around sebaceous glands to loosen, making pores appear larger. If CICA EVs support collagen production, pore improvement and elasticity recovery are two outcomes of the same underlying change.
Achieving both within 28 days in a small but controlled trial suggests the mechanism is active at practical usage frequencies and concentrations.
How It Fits Into a Routine
CICA EV formulations currently appear mainly as ampoules and serums, applied early in the routine after cleansing, before heavier moisturizers. When layering with retinoids or acid-based actives, sequencing matters. Using the CICA EV product first helps reinforce barrier function before introducing more aggressive ingredients.
The pilot study scale (20 participants) calls for confirmation in larger trials, but the direction of the evidence is consistent with earlier mechanistic and in vitro data on Centella triterpenoids.